27618260|t|From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen - binding domain
27618260|a|A variety of approaches are being pursued to improve the safety and antitumor potency of chimeric antigen receptor (CAR) T-cell therapy. However, most engineering efforts have thus far been focused on its intracellular signaling domain, while its extracellular antigen - binding domain has received less attention. Areas covered: Herein, the authors summarize the current knowledge of CAR T-cell therapy. Accordingly, they focus on its antigen - binding domain, discuss key considerations for selecting an optimal single-chain variable fragment (scFv) when designing a CAR, and suggest potential directions aimed at developing the next-generation CARs. Expert opinion: The extracellular region of CARs can play a decisive role in their safety and efficacy. Instead of directly translating an available therapeutic mAb to a scFv-based CAR construct, the authors suggest that various CAR - displayed scFvs with different affinity, specificity and binding epitopes against an individual target molecule should be generated and evaluated side-by-side. Incorporating new antibody formats that possess characteristics superior to those of scFvs may be one way to engineer safer and more effective CARs. The authors expect that further CAR engineering will enable us to target more antigens involved in hematological and solid malignancies with minimal side effects to serve unmet clinical needs.
27618260	17	27	antibodies	T103	UMLS:C0003241
27618260	31	57	chimeric antigen receptors	T103	UMLS:C4039583
27618260	59	63	CARs	T103	UMLS:C4039583
27618260	80	84	CARs	T103	UMLS:C4039583
27618260	94	101	antigen	T103	UMLS:C0003320
27618260	104	118	binding domain	T082	UMLS:C1514535
27618260	164	171	improve	T033	UMLS:C0184511
27618260	187	204	antitumor potency	T033	UMLS:C0243095
27618260	208	254	chimeric antigen receptor (CAR) T-cell therapy	T058	UMLS:C4289797
27618260	270	289	engineering efforts	T058	UMLS:C0033629
27618260	324	337	intracellular	T082	UMLS:C0178719
27618260	338	354	signaling domain	T082	UMLS:C0002518
27618260	366	379	extracellular	T017	UMLS:C0521119
27618260	380	387	antigen	T103	UMLS:C0003320
27618260	390	404	binding domain	T082	UMLS:C1514535
27618260	461	468	authors	T097	UMLS:C3812881
27618260	483	500	current knowledge	T170	UMLS:C0376554
27618260	504	522	CAR T-cell therapy	T058	UMLS:C4289797
27618260	555	562	antigen	T103	UMLS:C0003320
27618260	565	579	binding domain	T082	UMLS:C1514535
27618260	589	607	key considerations	T033	UMLS:C0518609
27618260	633	663	single-chain variable fragment	T103	UMLS:C1883036
27618260	665	669	scFv	T103	UMLS:C1883036
27618260	688	691	CAR	T103	UMLS:C4039583
27618260	715	725	directions	T082	UMLS:C0439755
27618260	766	770	CARs	T103	UMLS:C4039583
27618260	792	812	extracellular region	T017	UMLS:C0521119
27618260	816	820	CARs	T103	UMLS:C4039583
27618260	933	936	mAb	T103	UMLS:C0003250
27618260	942	952	scFv-based	T103	UMLS:C1883036
27618260	953	956	CAR	T103	UMLS:C4039583
27618260	972	979	authors	T097	UMLS:C3812881
27618260	1001	1004	CAR	T103	UMLS:C4039583
27618260	1017	1022	scFvs	T103	UMLS:C1883036
27618260	1064	1071	binding	T038	UMLS:C1167622
27618260	1072	1080	epitopes	T103	UMLS:C0003316
27618260	1143	1152	evaluated	T058	UMLS:C0220825
27618260	1185	1201	antibody formats	T103	UMLS:C0003241
27618260	1231	1239	superior	T082	UMLS:C1282910
27618260	1252	1257	scFvs	T103	UMLS:C1883036
27618260	1310	1314	CARs	T103	UMLS:C4039583
27618260	1320	1327	authors	T097	UMLS:C3812881
27618260	1348	1351	CAR	T103	UMLS:C4039583
27618260	1352	1363	engineering	T058	UMLS:C0033629
27618260	1394	1402	antigens	T103	UMLS:C0003320
27618260	1415	1428	hematological	T038	UMLS:C0376545
27618260	1433	1451	solid malignancies	T038	UMLS:C0006826
27618260	1465	1477	side effects	T038	UMLS:C0879626